ArticleFrontiers in molecular biosciences2025
Preoperative serum inflammatory markers in the prognostic assessment of hepatocellular carcinoma resection in stages I/II.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated clinicopathological model versus TNM for predicting survival in resected hepatocellular carcinoma: a retrospective cohort study.BMC gastroenterology · 2026Article
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a global health challenge, with early-stage resection offering the best chance for improved outcomes. However, limitations of the TNM staging system highlight the need for additional prognostic tools. This study evaluates the prognostic value of preoperative serum inflammatory markers in patients with stage I/II HCC undergoing surgical resection. Methods: A retrospective cohort study was conducted on 410 HCC patients (stage I/II) who underwent surgical resection at the Affiliated Hospital of North Sichuan Medical College between November 2011 and March 2020. Clinical and serological data, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and platelet-to-neutrophil ratio (PNR), were analyzed. Prognostic factors for overall survival (OS) were identified through univariate and multivariate Cox regression analyses. A nomogram was developed to predict 1-year, 3-year, and 5-year OS, with its performance assessed using ROC curves, calibration plots, and decision curve analysis (DCA). Kaplan-Meier survival curves were used to compare risk groups, and the model's predictive efficacy was evaluated against the AJCC 8th Edition TNM staging system. Results: Multivariate Cox regression identified NLR, PLR, ALBI score, AFP levels, and HBeAg status as independent prognostic factors for OS. The nomogram demonstrated superior discriminatory power (AUC: 0.78, 0.74, and 0.71 for 1-, 3-, and 5-year OS, respectively) compared to TNM staging. Kaplan-Meier analysis revealed significantly worse OS in the high-risk group (log-rank Conclusion: Preoperative serum inflammatory markers, when integrated with traditional TNM staging, significantly improve prognostic accuracy for stage I/II HCC patients undergoing surgical resection. The developed nomogram provides a practical tool for individualized risk stratification and may guide postoperative management to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.